Needham analyst David Saxon reiterated a Buy rating on NuVasive (NUVA – Research Report) today and set a price target of $53.00. The company’s shares closed yesterday at $44.82.
According to TipRanks, Saxon is an analyst with an average return of -14.8% and a 18.07% success rate. Saxon covers the Healthcare sector, focusing on stocks such as Irhythm Technologies, Alcon, and Azenta.
Currently, the analyst consensus on NuVasive is a Moderate Buy with an average price target of $58.29.
See today’s best-performing stocks on TipRanks >>
NUVA market cap is currently $2.31B and has a P/E ratio of -53.41.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NuVasive, Inc. engages in the development of minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. It offers cervical and spine fusion surgery, cervical plating, and posterior fixation products. The company was founded by Alexis V. Lukianov on July 21, 1997 and is headquartered in San Diego, CA.
